Kingswood Wealth Advisors LLC Has $830,000 Position in Astrazeneca Plc $AZN

Key Points

• Kingswood Wealth Advisors increased its stake in AstraZeneca by 180.8% in Q4, owning 9,024 shares after adding 5,810 shares, with holdings worth about $830,000 at quarter-end.
• Several large institutions — including Bank of Montreal, Holocene Advisors, Raymond James, Bank of America and Allspring — significantly raised their AZN positions recently, and institutional investors now own roughly 20.35% of the company.
• Analyst sentiment is mixed but generally favorable: eight analysts rate AZN a Buy and one a Sell, producing a consensus rating of "Moderate Buy" and a consensus target price of $102.67.

Kingswood Wealth Advisors LLC lifted its position in shares of Astrazeneca Plc (NYSE:AZN - Free Report) by 180.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,024 shares of the company's stock after buying an additional 5,810 shares during the period. Kingswood Wealth Advisors LLC's holdings in Astrazeneca were worth $830,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of AZN. Bank of Montreal Can raised its holdings in Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company's stock worth $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Holocene Advisors LP raised its holdings in Astrazeneca by 41.8% during the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company's stock worth $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Raymond James Financial Inc. raised its holdings in Astrazeneca by 64.8% during the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company's stock worth $264,373,000 after acquiring an additional 1,487,662 shares in the last quarter. Bank of America Corp DE raised its holdings in Astrazeneca by 4.7% during the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company's stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in Astrazeneca by 750.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,628,771 shares of the company's stock valued at $149,147,000 after acquiring an additional 1,437,253 shares during the last quarter. Institutional investors own 20.35% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on AZN. Weiss Ratings initiated coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a "buy (b)" rating for the company. TD Cowen restated a "buy" rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Barclays restated an "overweight" rating on shares of Astrazeneca in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a "sell" rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $102.67.

Astrazeneca Stock Down 1.3%

AZN opened at $189.71 on Friday. Astrazeneca Plc has a 12-month low of $132.32 and a 12-month high of $212.71. The company has a market capitalization of $294.22 billion, a PE ratio of 32.68, a price-to-earnings-growth ratio of 1.45 and a beta of 0.35. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51.

Astrazeneca Dividend Announcement

The firm also recently disclosed a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were given a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca's dividend payout ratio (DPR) is presently 74.83%.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.